Summit Therapeutics (SMMT) Free Cash Flow (2017 - 2026)
Summit Therapeutics' (SMMT) quarterly Free Cash Flow came in at -$141.3 million in Q2 2026, down 104.85% YoY from $2.9 billion in Q2 2025, and down 14.62% on a QoQ basis from -$123.3 million in Q1 2026.
Summit Therapeutics (SMMT) Free Cash Flow (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 10 years of Free Cash Flow data on file, last reported at -$141.3 million in Q2 2026.
- Quarterly Free Cash Flow fell 104.85% year-over-year to -$141.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$456.7 million (down 114.26% YoY) and the FY2025 annual result came in at -$323.6 million, down 127.49% from the prior year.
- Free Cash Flow eased to -$141.3 million in Q2 2026, from -$123.3 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $5.2 million in Q4 2022 to a low of -$141.3 million in Q2 2026.
- A 5-year average of -$47.2 million and a median of -$29.8 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow jumped 155.93% — and 2023, when it slumped 474.18%.
- Tracing SMMT's Free Cash Flow over 5 years: stood at $5.2 million in 2022, then tumbled by 474.18% to -$19.5 million in 2023, then slumped by 163.44% to -$51.3 million in 2024, then plunged by 91.28% to -$98.1 million in 2025, then slumped by 44.13% to -$141.3 million in 2026.
- The last three Free Cash Flow figures came in at -$141.3 million (Q2 2026), -$123.3 million (Q1 2026), and -$98.1 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | -141.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -141.34 Mn |
| Jun 30, 2026 | -141.34 Mn |
| Mar 31, 2026 | -123.32 Mn |
| Mar 31, 2026 | -123.32 Mn |
| Dec 31, 2025 | -98.07 Mn |
| Dec 31, 2025 | -98.07 Mn |
| Sep 30, 2025 | -93.94 Mn |
| Sep 30, 2025 | -93.94 Mn |
| Jun 30, 2025 | -69.00 Mn |
| Jun 30, 2025 | -69.00 Mn |
| Mar 31, 2025 | -62.59 Mn |
| Mar 31, 2025 | -62.59 Mn |
| Dec 31, 2024 | -51.27 Mn |
| Dec 31, 2024 | -51.27 Mn |
| Sep 30, 2024 | -30.28 Mn |
| Sep 30, 2024 | -30.28 Mn |
| Jun 30, 2024 | -33.01 Mn |
| Jun 30, 2024 | -33.01 Mn |
| Mar 31, 2024 | -27.69 Mn |
| Mar 31, 2024 | -27.69 Mn |